Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CEACAM-6

CEACAM-6

Brief Information

Name:Carcinoembryonic antigen related cell adhesion molecule 6
Target Synonym:CEACAM6,CD66c,NCA,Carcinoembryonic Antigen Related Cell Adhesion Molecule 6,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 (Non-Specific Cross Reacting Antigen),Normal Cross-Reacting Antigen,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6,Non-Specific Crossreacting Antigen,Cluster Of Differentiation 66c,CD66c Antigen,CEAL,CEA Cell Adhesion Molecule 6
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CE6-H5254-ELISA
 CEACAM-6 ELISA

Immobilized Human CEACAM-8, His Tag (Cat. No. CE8-H5224) at 5 μg/mL (100 μL/well) can bind Human CEACAM-6, Fc Tag (Cat. No. CE6-H5254) with a linear range of 0.01-0.156 μg/mL (QC tested).

CE6-H82F6-MALS-HPLC
CEACAM-6 MALS images

The purity of Biotinylated Human CEACAM-6, Fc,Avitag (Cat. No. CE6-H82F6) is more than 90% and the molecular weight of this protein is around 170-190 kDa verified by SEC-MALS.

Synonym Name

CEACAM6,CD66c,CEAL,NCA

Background

Carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) (CEACAM6) is also known as CD66c (Cluster of Differentiation 66c), CEAL, NCA, and is one of seven human CEACAM family members within the immunoglobulin superfamily. In humans, CEACAMs include type I transmembrane proteins (CEACAM1, CEACAM3, and CEACAM4) and GPI-linked molecules (CEACAM5 through CEACAM8). There is no human CEACAM2. CEACAM 6 contains one N-terminal V-type Ig-like domain (N domain), followed by two C2-type Ig-like domains. It shows considerable glycosylation, including (sialyl) LewisX, which mediates binding to E-selectin, galectins and some bacterial fimbrae. CEACAM-6 is expressed by granulocytes and their progenitors. It is also expressed by epithelia of various organs and is upregulated in pancreatic and colon adenocarcinomas, as well as hyperplastic polyps. Resistance to adhesion-related apoptosis in tumor cells is conferred in the condition of CEACAM6 overexpression.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
NEO-201 NEO-201 Phase 2 Clinical Precision Biologics Inc, National Cancer Institute Squamous Cell Carcinoma of Head and Neck; Uterine Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
L-DOS-47 L-DOS-47 Phase 2 Clinical Helix Biopharma Adenocarcinoma of Lung; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung Details
EBC-129 EBC-129; EBC129 Phase 1 Clinical Experimental Drug Development Centre Solid tumours Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message